A Prospective, Single-Arm, Phase II Clinical Study of Nimotuzumab Combined With Radiotherapy for Elderly Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck

This is a prospective, single-center, open-label, single-arm phase II study. The purpose of this study is to evaluate the efficacy and safety of nimotuzumab combined with concurrent intensity-modulated radiotherapy (IMRT) in elderly patients (≥65 years old) with locally advanced unresectable head-and-neck squamous cell carcinoma (HNSCC) who are unfit for standard concurrent cisplatin-based chemoradiotherapy. Eligible patients will receive standard-dose intensity-modulated radiotherapy together with weekly nimotuzumab. The primary endpoint is 1-year overall survival rate. Secondary endpoints include progression-free survival, objective tumor response rate, locoregional control rate, distant metastasis rate, and treatment-related adverse events. Patients will be followed up for survival, tumor status and safety assessments after treatment completion.

开始日期2026-09-10

申办/合作机构

北京协和医院

NCT07736612

/ Not yet recruiting临床1/2期IIT

A Phase Ib/II Study of the Safety, Tolerability, and Efficacy of a Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer

This study aims to evaluate the safety, tolerability, and efficacy of HRS-2329 in combination with other anti-tumor therapies in participants with advanced pancreatic cancer harboring RAS mutations or amplifications.

开始日期2026-08-15

申办/合作机构

浙江大学

ChiCTR2600128718

/ Suspended临床2期IIT

A Prospective, Single-Arm, Phase II Clinical Study of Nimotuzumab Combined with Neoadjuvant Chemotherapy in the Treatment of Locally Advanced Resectable Oral Squamous Cell Carcinoma

开始日期2026-08-01

申办/合作机构

浙江大学医学院附属第一医院（浙江省第一医院）

100 项与尼妥珠单抗相关的临床结果

登录后查看更多信息

100 项与尼妥珠单抗相关的转化医学

登录后查看更多信息

100 项与尼妥珠单抗相关的专利（医药）

登录后查看更多信息

360

项与尼妥珠单抗相关的文献（医药）

2026-11-01·INTERNATIONAL JOURNAL OF CANCER

Nimotuzumab Combined With Concurrent Curative Radiotherapy and S‐1 in 75 Years and Older Patients With Stage II ‐ IVB Esophageal Squamous Cell Carcinoma: A Phase II Study

Article

作者: Ge, Xiaolin ; Sun, Xinchen ; Chen, Hui ; Xia, Xiaojie ; Xu, Lu ; Yan, Jingze

ABSTRACT:

Concurrent chemoradiotherapy is the standard treatment for inoperable, locally advanced esophageal cancer. However, older patients often have reduced tolerance to radiotherapy and concurrent intravenous chemotherapy due to declining physical function and multiple comorbidities. This prospective, single‐center, phase II study assessed the efficacy and safety of nimotuzumab, an epidermal growth factor receptor antagonist, combined with concurrent radiotherapy and S‐1 in patients 75 years and older. A total of 56 patients were enrolled, with the primary endpoint being progression‐free survival (PFS), while secondary endpoints included overall survival (OS), objective response rate, disease control rate, treatment‐related adverse events, nutritional indicators, and quality of life (QOL). Most nutritional indicators remained stable after treatment. As of June 2024, the median follow‐up duration was 24.1 months (8.8–34.1). Eleven patients achieved complete response, 39 achieved partial response, five had stable disease, and one experienced progressive disease. The median PFS was 25.3 months (95% CI, 16.5–34.1), while the median OS was 28.2 months (95% CI, 24.1–32.3). Most adverse events were grade 1–2 (85.7%). Among survivors, 45.5% reported high satisfaction with their QOL, and 84.8% did not experience weight loss. This combination therapy demonstrated promising efficacy and safety, suggesting it may be a viable treatment option for this patient population.

2026-10-01·Clinical Pharmacology in Drug Development

A Phase I Study of Nimotuzumab Combined with Irinotecan in Chinese Patients with Advanced Solid Tumors

Article

作者: Jiang, Zhichao ; Du, Chunxia ; Sun, Yongkun ; Zhou, Aiping ; Zhang, Wen

Abstract:

Nimotuzumab is an anti‐epidermal growth factor receptor antibody. This Phase I study evaluated the pharmacokinetics and safety of nimotuzumab plus irinotecan in Chinese patients with advanced solid tumors. At single ascending dosage (SAD) stage, four cohorts (100, 200, 400, and 600 mg) of patients received nimotuzumab intravenously on Day 1, alongside irinotecan 180 mg/m 2 on Day 8. Three weeks later, all patients in the four cohorts transferred to multiple ascending dosage (MAD) stage: nimotuzumab was administrated weekly for 6 weeks, alongside irinotecan (Days 1, 15, 29, 43, and 57, 180 mg/m 2 ). Primary objective was pharmacokinetics, safety and tolerability was also examined. From December 2012 to October 2014, in SAD and MAD stages, there were 28 and 39 patients with Stage IV solid tumors. The area under the concentration curve (AUC 0–∞ ) for a single dose of nimotuzumab was 10.2 ± 2.7 (100 mg), 37.6 ± 10.0 (200 mg), 114.8 ± 35.5 (400 mg), 197.6 ± 32.0 (600 mg) (×100 h µg/mL), and for multiple dose, it was 26.7 ± 3.4 (100 mg), 87.1 ± 12.0 (200 mg), 193.4 ± 46.9 (400 mg) and 446.3 ± 100.7 (600 mg) (×100 h µg/mL). There was low incidence of rash and no dose‐limiting toxicities occurred. This study indicated that nimotuzumab at doses ranging from 100 to 600 mg exhibited a manageable and tolerable safety profile.

2026-09-01·EClinicalMedicine

Efficacy and safety of liposomal irinotecan plus nimotuzumab in immune checkpoint inhibitor-refractory recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase II trial

Article

作者: Wang, Lin ; He, Shuiqing ; Tang, Linquan ; Chen, Chunyan ; Ye, Yanfang ; Bei, Wei-Xin ; Zhao, Ze-Yu ; Lv, Shuhui ; Lu, Nian ; Xiang, Yan-Qun ; Liu, Liting

Background:

Patients with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) who progress after immune checkpoint inhibitor (ICI) therapy have limited treatment options and poor outcomes. We evaluated the efficacy and safety of liposomal irinotecan plus nimotuzumab in patients with epidermal growth factor receptor (EGFR)-positive, ICI-refractory R/M NPC.

Methods:

In this single-arm, open-label, phase II trial (NCT06414577) conducted in China, patients with EGFR-positive, ICI-refractory R/M NPC were enrolled between May 27, 2024, and January 9, 2025. Patients received intravenous liposomal irinotecan (70 mg/m²) plus nimotuzumab (400 mg) every 2 weeks for up to eight cycles. The primary endpoint was objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1.

Findings:

Thirty-six heavily pretreated patients were enrolled, of whom 12 (33.3%) had received three or more prior lines of therapy for advanced disease. In the intention-to-treat population, 13 of 36 patients achieved an objective response (ORR 36.1%; 95% CI 20.8-53.8), and 22 of 36 patients achieved disease control (61.1%). Median progression-free survival was 3.0 months (95% CI, 2.2-4.1), and median duration of response was 2.3 months (95% CI 1.5-3.1). After a median follow-up of 22.0 months, the median overall survival was 14.1 months (95% CI, 8.7-not estimable). Grade 3 or higher treatment-related adverse events occurred in eight of 36 patients (22.2%), and no treatment-related deaths were observed. In a post-hoc exploratory analysis, an early decline of at least 50% in plasma Epstein-Barr virus DNA was associated with a higher ORR.

Interpretation:

Liposomal irinotecan plus nimotuzumab showed preliminary antitumor activity and manageable safety in heavily pretreated patients with ICI-refractory R/M NPC. However, response durability was limited, and further comparative studies are needed to evaluate its clinical value and identify patients most likely to derive durable benefit.

Funding:

Supported by grants from the National Natural Science Foundation of China, Science and Technology Program of Guangdong Esophageal Cancer Institute, and China Postdoctoral Science Foundation.

134

项与尼妥珠单抗相关的新闻（医药）

2026-10-03

·雪儿学堂

【2026ESMO】胰腺癌篇章新进展全局观

“ KRAS 从「不可成药」到制药工业最拥挤的赛道，围手术期抑制剂与治疗性疫苗同时推进，胰腺癌的治疗逻辑正在被重写。 —— ESMO 2026 消化道肿瘤摘要解读系列胰腺癌是消化道肿瘤中预后最差的瘤种，也是本届 ESMO 投入最集中的领域之一。我们提取到胰腺癌相关摘要 138 条，体量在六大瘤种中位列第二，其中包含 2 场口头报告、多项 III 期研究和正在进行的一线随机试验。本文把 138 条摘要归为四条战线：KRAS 靶向、免疫与治疗性疫苗、局部治疗强化、化疗策略与真实世界证据，文末附完整清单。 📌 本文看点 01 KRAS G12D 的临床化路径 02 4 项 LBA 密集披露 03 围手术期与局部强化 01 DATA SCAN数据概览：138 条摘要，四大方向同时推进 138 条摘要的形式分布以 Poster 与 ePoster 为主，但看点高度集中在少数重磅研究上：2 场口头报告、4 项 LBA、多项一线 III 期与围手术期研究。中国研究者贡献 30 条摘要，覆盖 KRAS G12D 靶向、真实世界数据与局部治疗。从研究类型看，胰腺癌的方向分化特别明显——一类研究解决「用什么药」，一类解决「什么时候用、联合什么」。 138 胰腺癌相关摘要（条） 2 / 7 口头报告 / 进行中试验 33 中国讲者摘要（条） 129 Poster 与 ePoster 一句话结论：胰腺癌的新药竞争已从化疗骨架的排列组合，转向KRAS 精准靶向与免疫治疗性疫苗。 02 HIGHLIGHTS重磅研究解读本届胰腺癌的口头报告与 4 项 LBA 覆盖了靶向、免疫、局部强化与化疗策略四条主线。 CASE 3137RORapid Oral 新型口服KRAS G12D抑制剂INCB161734联合化疗治疗晚期/转移性胰腺导管腺癌（PDAC）患者的安全性与疗效 Safety and Efficacy of INCB161734, a Novel Oral KRAS G12D Inhibitor, in Combination with Chemotherapy in Patients (pts) with Advanced/Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) 讲者：Antoine Hollebecque (Villejuif, France) 新型口服 KRAS G12D 抑制剂 INCB161734 联合化疗的早期数据，是本届口头报告中最受关注的新机制之一。G12D 是胰腺癌最主要的 KRAS 突变亚型，口服小分子的可及性优势，将直接影响这一赛道的落地速度。 CASE LBA82LBA · 优选论文 RAS(ON) 多选择性抑制剂 daraxonrasib 对比化疗用于经治转移性胰腺导管腺癌：III 期 RASolute 302 研究补充亚组分析 Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma: additional subgroup analyses from the Ph3 RASolute 302 study 讲者：Zev A. Wainberg｜洛杉矶，美国 RASolute 302 是 KRAS 抑制剂首次在胰腺癌经治人群中以 III 期形式呈现，本届公布补充亚组分析。「多选择性 RAS(ON) 抑制剂」意味着它不再局限于单一突变亚型，这对突变谱分散的胰腺癌尤为关键。 CASE LBA85LBA · 快速口头报告 HRS-4642 联合化疗±阿得贝利单抗用于 KRAS G12D 突变胰腺癌围手术期治疗：II 期研究初步结果 HRS-4642 plus chemotherapy ± adebrelimab as perioperative therapy in KRAS G12D-mutant pancreatic cancer: preliminary results of a phase 2 study 讲者：沈柏用｜上海交通大学医学院附属瑞金医院国产 KRAS G12D 抑制剂 HRS-4642 直接把适应场景前移到围手术期，并叠加 PD-L1 抗体。这类「靶向+免疫+化疗」的围手术期组合，是本届胰腺癌最具想象力的设计之一。 CASE LBA83LBA · 优选论文七价 mKRAS 特异性淋巴结靶向两亲性免疫治疗对比观察用于已切除胰腺导管腺癌：AMPLIFY-7P 随机 II 期研究 Seven-Valent mKRAS-specific lymph node targeted amphiphile immunotherapy versus observation in resected pancreatic ductal adenocarcinoma: the AMPLIFY-7P randomized phase 2 study 讲者：Eileen M. O’Reilly｜纽约，美国 AMPLIFY-7P 用七价 KRAS 特异性治疗性疫苗挑战术后观察，是免疫治疗在胰腺癌最艰难场景（微小残留病灶）中的一次正面尝试。淋巴结靶向递送技术能否突破胰腺癌的低免疫原性，值得跟踪。 CASE 3136RORapid Oral mFOLFIRINOX±SBRT治疗高危、交界可切除或局部晚期胰腺癌的随机II期研究：AGITG MASTERPLAN试验结果 Randomised Phase II study of mFOLFIRINOX±SBRT in patients with high risk, borderline resectable or locally advanced pancreatic cancer: Results of the AGITG MASTERPLAN trial 讲者：Andrew Oar (Southport, Australia) AGITG MASTERPLAN 研究评估 mFOLFIRINOX±SBRT 用于高危、边缘可切除或局部晚期胰腺癌。SBRT 的加入能否提高可切除转化率，是这项随机 II 期最有临床价值的问题。 CASE LBA84LBA · 快速口头报告一线治疗失败晚期胰腺癌，双药对比单药治疗的随机、多中心、开放标签、双臂 III 期研究（Panc-SELECT——吉西他滨队列） A randomized, multicenter, open-label, double-arm, phase III study of doublet vs monotherapy in advanced pancreatic cancer patients who have failed first-line therapy (Panc-SELECT — gemcitabine arms) 讲者：Prabhat G. Bhargava｜孟买，印度 Panc-SELECT 关注一个很实际的问题：一线失败后，二线到底该用双药还是单药。在体能状态普遍下降的胰腺癌二线人群中，这类研究直接决定临床路径。 CASE 3190TiPTrial in Progress poster setidegrasib联合mFOLFIRINOX或NALIRIFOX一线治疗KRAS G12D突变转移性胰腺导管腺癌（PDAC）的3期双盲随机试验：进行中的试验 A Phase 3, double-blind, randomized trial of setidegrasib + mFOLFIRINOX or NALIRIFOX as first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (PDAC) harboring KRAS G12D mutations: Trial in progress 讲者：Teresa Macarulla Mercade (Barcelona, Spain) setidegrasib 联合 mFOLFIRINOX 或 NALIRIFOX 一线治疗 KRAS G12D 突变胰腺癌的 III 期双盲随机研究。KRAS G12D 抑制剂正式进入一线III期梯队，这是本届胰腺癌在研管线最重要的信号。 CASE 3147PPoster 多药联合化疗对比吉西他滨治疗体弱或老年晚期胰腺癌（MaGPiE）：一项III期随机试验的中期安全性分析 Multi-agent chemotherapy versus gemcitabine in frail or elderly advanced pancreatic cancer (MaGPiE), interim safety analysis of a phase III randomised trial 讲者：Vikas S. Ostwal (Mumbai, India) MaGPiE III 期中期安全性分析：多药联合化疗对比吉西他滨用于体弱或老年晚期胰腺癌。在体能状态受限人群中寻找「减毒而不减效」的方案，比在优势人群中做加法更有现实意义。 03 TRENDS研究方向盘点四条战线各自都有明确的问题清单。 KRAS 靶向：从单亚型到多选择性 INCB161734（3137RO）、daraxonrasib（LBA82）、setidegrasib（3190TiP）、HRS-4642（LBA85）构成完整梯队。从后线到一线、从单药到联合化疗，KRAS 抑制剂的临床化路径已经清晰，接下来比拼的是疗效深度与耐药管理。免疫与治疗性疫苗：从小样本到随机对照 mKRAS 七价疫苗（LBA83）、atebimetinib 联合化疗的一线 III 期（3189TiP）、以及多项免疫联合探索，共同回答「胰腺癌的冷肿瘤属性能否被打破」。局部治疗强化：可切除边界的再定义 mFOLFIRINOX±SBRT（3136RO）与多项新辅助/转化研究，试图用放疗与更强化疗把边缘可切除人群推向 R0 切除。化疗策略与真实世界证据：被低估的部分 Panc-SELECT（LBA84）解决二线双药与单药之争，MaGPiE（3147P）关注老年体弱人群，奥拉帕利维持治疗的真实世界评价（3216eP）则补充了 BRCA 突变人群在临床实践中的表现。 04 FULL LIST完整摘要清单以下为本届 ESMO 胰腺癌相关全部 138 条摘要（中国讲者 30 条），按摘要编号排序。中文题目为 AI 辅助翻译，仅供检索参考。摘要编号作者（讲者）题目（中文 / 英文） 2902P Chao Li (Beijing, China) 基于VHH的抗CLDN18.2 CAR-T疗法IMC002治疗胃/胃食管结合部癌和胰腺癌的I/IIa期试验：持久的缓解与良好的安全性Durable responses with a favorable safety profile in a phase I/IIa trial of IMC002, a VHH-based anti-CLDN18.2 CAR-T therapy for gastric/gastroesophageal junction and pancreatic cancers 3012eP Stephen L. Slocum (Daejeon, Republic of Korea) LCB02A：一种靶向Claudin 18.2的ADC，用于治疗胃癌、胰腺癌及其他Claudin 18.2表达肿瘤LCB02A, a Claudin 18.2-directed ADC, for the Treatment of Gastric, Pancreatic, and Other Claudin 18.2-Expressing Cancers 3136RO Andrew Oar (Southport, Australia) mFOLFIRINOX±SBRT治疗高危、交界可切除或局部晚期胰腺癌的随机II期研究：AGITG MASTERPLAN试验结果Randomised Phase II study of mFOLFIRINOX±SBRT in patients with high risk, borderline resectable or locally advanced pancreatic cancer: Results of the AGITG MASTERPLAN trial 3137RO Antoine Hollebecque (Villejuif, France) 新型口服KRAS G12D抑制剂INCB161734联合化疗治疗晚期/转移性胰腺导管腺癌（PDAC）患者的安全性与疗效Safety and Efficacy of INCB161734, a Novel Oral KRAS G12D Inhibitor, in Combination with Chemotherapy in Patients (pts) with Advanced/Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) 3138P Shinji Itoh (Fukuoka, Japan) 使用基于全基因组测序的ctDNA检测可切除胰腺癌的分子残留病灶（MRD）：MONSTAR-SCREEN-3的初步发现Molecular Residual Disease Detection for Resectable Pancreas Cancer Using a whole-genome sequencing-based ctDNA assay: Initial findings from the MONSTAR-SCREEN-3 3139P Casper W.F. Van Eijck (Rotterdam, Netherlands) 血浆ctDNA甲基化单倍型图谱作为胰腺导管腺癌FOLFIRINOX方案疗效的预测性生物标志物Plasma ctDNA methylation haplotype profiling as a predictive biomarker for FOLFIRINOX response in pancreatic ductal adenocarcinoma 3140P Dan Zhao (Houston, United States of America) KRAS Q61突变胃肠道恶性肿瘤的等位基因特异性特征及其与胰腺癌临床结局和转录组特征的关系Allele Specific Characteristics of KRASQ61 Mutated Gastrointestinal Malignancies with Clinical Outcomes and Transcriptomic Features in Pancreatic Cancer 3141P Ashish Sharma (New Haven, United States of America) 最大PDAC基因组数据集中种族和民族数据的完全缺失阻碍了对新兴等位基因剂量生物标志物的公平性相关验证：一项数据治理审计Complete absence of race and ethnicity data in the largest PDAC genomic dataset prevents equity-relevant validation of emerging allele dosage biomarkers: a data governance audit 3142P Ashish Sharma (New Haven, United States of America) KRAS等位基因身份和肿瘤突变负荷（TMB）无法区分胰腺导管腺癌中的超常应答者与快速进展者：一项质疑等位基因决定论的阶段匹配极端表型分析KRAS allele identity and tumour mutational burden do not differentiate exceptional responders from rapid progressors in pancreatic ductal adenocarcinoma: a stage-matched extreme-phenotype analysis questioning allele determinism 3143P Christoph Gerdes (Toronto, Canada) 胰腺癌的转录组学重新分类揭示新的分子亚型Transcriptomic Reclassification of Pancreatic Cancer Uncovers Novel Molecular Subtypes 3144P Franck MONNIEN (Besançon, France) 基质HSP47和膜β-catenin作为胰腺导管腺癌辅助化疗获益的预后和预测性生物标志物：模型构建与独立验证Stromal HSP47 and membranous β-catenin as prognostic and predictive biomarkers of adjuvant chemotherapy benefit in pancreatic ductal adenocarcinoma: development and independent validation 3145P Dongsheng Zhang (Guangzhou, China) 维迪西妥单抗（Disitamab Vedotin）治疗HER2表达局部晚期或转移性胰腺癌：一项前瞻性、单臂、II期临床试验Disitamab Vedotin in HER2-Expressing Locally Advanced or Metastatic Pancreatic Cancer: A Prospective, Single-Arm, Phase II Clinical Trial 3146P Vincent Chung (Duarte, United States of America) 仑伐替尼-帕博利珠单抗维持治疗晚期胰腺导管腺癌（PDAC）：II期试验（NCT04887805）结果及免疫相关标志物Lenvatinib-pembrolizumab maintenance therapy in advanced pancreatic ductal adenocarcinoma (PDAC): Phase II trial (NCT04887805) results and immunological correlatives 3147P Vikas S. Ostwal (Mumbai, India) 多药联合化疗对比吉西他滨治疗体弱或老年晚期胰腺癌（MaGPiE）：一项III期随机试验的中期安全性分析Multi-agent chemotherapy versus gemcitabine in frail or elderly advanced pancreatic cancer (MaGPiE), interim safety analysis of a phase III randomised trial 3148P Shinichiro Takahashi (Makinohara, Japan) 新辅助吉西他滨联合白蛋白结合型紫杉醇对比基于S-1的放化疗治疗交界可切除胰腺癌的II/III期试验5年更新（GABARNANCE）5-year update of the phase II/III trial of neoadjuvant gemcitabine plus nab-paclitaxel versus S-1-based chemoradiotherapy for borderline resectable pancreatic cancer (GABARNANCE) 3149P Alexander I. Spira (Fairfax, United States of America) vopimetostat联合daraxonrasib或zoldonrasib治疗MTAP缺失、RAS突变（MTAPdel/RASmut）转移性PDAC和NSCLC患者的1/2期研究A Phase 1/2 study of vopimetostat in combination with daraxonrasib or zoldonrasib in patients with MTAP deleted RAS mutated (MTAPdel/RASmut) metastatic PDAC and NSCLC 3150P Dan Cao (Chengdu, China) HRS-4642联合尼妥珠单抗（nimotuzumab）治疗KRAS G12D突变晚期胰腺导管腺癌患者的Ib/II期研究A Phase Ib/II Study of HRS-4642 plus Nimotuzumab in Patients with KRAS G12D-Mutant Advanced Pancreatic Ductal Adenocarcinoma 3151P David J. Pinato (London, United Kingdom) 辅助intismeran autogene联合FOLFIRINOX治疗可切除胰腺导管腺癌：一项I期研究结果Adjuvant intismeran autogene plus FOLFIRINOX in resectable pancreatic ductal adenocarcinoma: results from a phase I study 3152P Teresa Macarulla Mercade (Barcelona, Spain) 与Ibrilatazar联合FOLFIRINOX治疗后转移性胰腺癌结局改善相关的临床相关亚群：来自PanC-ASAP试验的探索性分析Clinically Relevant Subpopulations Associated with Improved Outcomes Following Ibrilatazar Plus FOLFIRINOX in Metastatic Pancreatic Cancer: An Exploratory Analyses from the PanC-ASAP Trial 3153P Salomon M. Stemmer (Petah Tikva, Israel) Namodenoson在晚期胰腺腺癌中实现持久的疾病稳定：一项2a期研究结果Durable Disease Stabilization with Namodenoson in Advanced Pancreatic Adenocarcinoma: Results from a Phase 2a Study 3154P Mette H. Nissen (Herlev, Denmark) 晚期胰腺癌的早期专科姑息治疗（EarlyCarePan）：一项丹麦全国性随机试验Early specialized palliative care in advanced pancreatic cancer (EarlyCarePan): a nationwide Danish randomized trial 3155P Rui Liu (Tianjin, China) QL1706联合西达本胺（chidamide）、白蛋白结合型紫杉醇和吉西他滨一线治疗转移性胰腺癌的疗效与安全性：一项前瞻性、单臂临床试验Efficacy and Safety of QL1706 Combined with Chidamide, Nab-Paclitaxel, and Gemcitabine as First-Line Treatment for Metastatic Pancreatic Cancer: A Prospective, Single-Arm Clinical Trial 3156P Shukui Qin (Nanjing, China) 索凡替尼（surufatinib）联合卡瑞利珠单抗、白蛋白结合型紫杉醇和吉西他滨一线治疗转移性胰腺癌的最终2期分析Final phase 2 analysis of surufatinib plus camrelizumab, nab-paclitaxel and gemcitabine in first-line metastatic pancreatic cancer 3157P Wen-Quan Wang (Shanghai, China) HRS-4642联合双免疫治疗和化疗治疗晚期胰腺癌：一项II期研究第1臂的初步结果HRS-4642 with dual immunotherapy and chemotherapy for advanced pancreatic cancer: Preliminary results from Arm 1 of a phase II study 3158P Huizi Sha (Nanjing, China) 派安普利单抗、安罗替尼与AG化疗联合作为转移性胰腺癌一线方案：一项多中心、随机对照试验（RCT-PAAG）Integrated Penpulimab, Anlotinib and AG Chemotherapy as First-Line Regimen for Metastatic Pancreatic Cancer: A Multi-Centered, Randomized Controlled Trial (RCT-PAAG) 3159P Xiang Kong (Nanjing, China) 脂质体伊立替康（nal-IRI）/5-FU/LV、贝莫苏拜单抗和安罗替尼联合（伴或不伴SBRT）二线治疗转移性胰腺癌：一项II期双队列研究Integrated nal-IRI/5-FU/LV, benmelstobart, and anlotinib with or without SBRT for second-line metastatic pancreatic cancer: A phase II dual-cohort study 3160P Songul Kucukcelebi (Rotterdam, Netherlands) 已切除胰腺癌接受基于树突状细胞的辅助免疫治疗后的长期临床结局和免疫谱分析：REACtiVe-1试验更新结果Long-term clinical outcomes and immune profiling after adjuvant dendritic cell-based immunotherapy in resected pancreatic cancer: updated REACtiVe-1 trial results. 3161P Huikai Li (Tianjin, China) 新辅助依沃西单抗（ivonescimab）联合吉西他滨/白蛋白结合型紫杉醇治疗交界可切除胰腺癌：一项前瞻性单臂II期试验Neoadjuvant ivonescimab plus gemcitabine/nab-paclitaxel for borderline resectable pancreatic cancer: a prospective single-arm phase II trial 3162P Haochen Tang (Nanjing, China) 尼妥珠单抗联合标准辅助化疗用于胰腺癌根治性切除术后：一项前瞻性单臂、双队列II期研究的初步结果Nimotuzumab plus standard adjuvant chemotherapy after curative resection for pancreatic cancer: preliminary results of a prospective single-arm, two-cohort phase II study 3163P Letizia Procaccio (Padua, Italy) PAXG方案对比(m)FOLFIRINOX一线治疗转移性胰腺癌患者：一项多中心目标试验模拟研究PAXG versus (m)FOLFIRINOX as first-line therapy for patients with metastatic pancreatic cancer: a multicenter, target trial emulation study 3164P Janet Graham (Glasgow, United Kingdom) PRIMUS-001：FOLFOX-A（FOLFOX/白蛋白结合型紫杉醇）对比AG（白蛋白结合型紫杉醇/吉西他滨）治疗转移性胰腺癌患者的适应性2期研究，并含生物标志物评估PRIMUS-001: An adaptive phase 2 study of FOLFOX-A (FOLFOX/nab-paclitaxel) versus AG (nab-paclitaxel/gemcitabine) in patients with metastatic pancreatic cancer, with biomarker evaluation 3165P Baiyong Shen (Shanghai, China) 围手术期HRS-4642、化疗和阿得贝利单抗治疗KRAS G12D突变胰腺癌：II期初步结果Perioperative HRS-4642, Chemotherapy, and Adebrelimab in KRAS G12D-Mutant Pancreatic Cancer: Preliminary Phase 2 Results 3166P Marc Hilmi (New York, United States of America) 表达骨膜蛋白（POSTN）的胰腺癌相关成纤维细胞（CAFs）定义了与肿瘤侵袭性和治疗反应相关的独特生态位：来自PRODIGE 24试验的证据Periostin (POSTN)-expressing pancreatic cancer-associated fibroblasts (CAFs) define a distinct niche associated with tumor aggressiveness and therapeutic response: evidence from PRODIGE 24 trial 3167P Laura K. Kjær (Herlev, Denmark) 纳武利尤单抗联合伊匹木单抗、TGFβ-15肽疫苗和立体定向体部放疗治疗难治性胰腺癌的I期研究（CheckVAC）Phase I study of nivolumab with ipilimumab combined with TGFβ-15 peptide vaccine and stereotactic body radiotherapy for refractory pancreatic cancer (CheckVAC) 3168P Jialin Li (Shanghai, China) 六周诱导吉西他滨联合白蛋白结合型紫杉醇（AG）后序贯索凡替尼联合AG或单用AG一线治疗局部晚期或转移性胰腺导管腺癌（mPDAC）：一项单中心、双队列II期研究Six Weeks of Induction Gemcitabine Plus Nab Paclitaxel (AG) Followed by Sequential Surufatinib Plus AG or AG alone as First Line Therapy for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC): A Single Center, Two Cohort, Phase II Study 3169P Xianjun Yu (Shanghai, China) TQB2868联合白蛋白结合型紫杉醇/吉西他滨±安罗替尼一线治疗转移性胰腺导管腺癌：一项前瞻性多中心双队列II期研究TQB2868 Plus Nab-Paclitaxel/Gemcitabine ± Anlotinib as First-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma: A Prospective Multicenter Two-Cohort Phase II Study 3170P Noha F. Rashad (Suez, Egypt) OligoPanc共识定义的寡转移胰腺导管腺癌作为预后分层工具对比其他定义标准的价值：一项回顾性验证研究（GI Characterize-PANC-1）The value of OligoPanc consensus definition of Oligometastatic pancreatic ductal adenocarcinoma as a prognostic stratification tool compared to alternative defining criteria: A retrospective validation study (GI Characterize-PANC-1). 3171P Guillaume Ulmann (Saint-Ouen-sur-Seine, France) 已切除胰腺癌营养不良的经济负担：一项全国性卫生经济学研究Economic Burden of Malnutrition in Resected Pancreatic Cancer: A Nationwide Health Economic Study 3172P Rafael Alvarez Gallego (Madrid, Spain) 接受脂质体伊立替康（nal-IRI）治疗的转移性胰腺导管腺癌（mPDAC）患者的长期生存：NALLONG研究与西班牙队列（NALLONG2）的汇总分析Long-term survival in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI): a pooled analysis of the NALLONG study and a Spanish cohort (NALLONG2) 3173P Ashish Sharma (New Haven, United States of America) KRAS突变拷贝增加与胰腺导管腺癌的转移表现共分离：1157例注释患者中等位基因剂量生物学的新拓展KRAS mutant copy gain co-segregates with metastatic presentation in pancreatic ductal adenocarcinoma: a novel extension of allele dosage biology in 1,157 annotated patients 3174P Antonio Pea (Verona, Italy) 基于病理学的导管内肿瘤相关胰腺癌复发风险模型，用于指导辅助治疗A Pathology-Based Recurrence Risk Model for Intraductal Neoplasm–Associated Pancreatic Carcinoma to Inform Adjuvant Therapy 3175P Giulia Orsi (Milan, Italy) 导管内乳头状黏液性肿瘤（IPMN）来源的胰腺导管腺癌：诊断和治疗意义Intraductal papillary mucinous neoplasm (IPMN)-derived Pancreatic Ductal Adenocarcinoma: diagnostic and therapeutic implications 3176P Minami Nomura (Minato-ku, Japan) SMAD4状态在不可切除胰腺导管腺癌中依赖背景的预后影响Context-dependent prognostic impact of SMAD4 status in unresected pancreatic ductal adenocarcinoma 3177P Marc Hilmi (New York, United States of America) 致病性ATM缺失定义了预后更佳、肝脏趋向性降低且具有独特KRAS-肿瘤微环境（TME）生物学的胰腺癌（PC）Pathogenic ATM loss defines pancreatic cancer (PC) with better prognosis, reduced liver tropism and distinct KRAS-tumor microenvironment (TME) biology 3178P Fieke E. Froeling (Glasgow, United Kingdom) Precision-Panc：英国胰腺癌治疗研发平台的经验与启示（NCT04161417）Precision-Panc: UK therapeutic development platform for pancreatic cancer, experience and lessons learnt (NCT04161417) 3179P Kamal Al-rabi (Amman, Jordan) PDAC的比较基因组图谱：来自中东和全球队列的见解Comparative Genomic Landscape of PDAC: Insights from Middle Eastern and Global Cohorts 3180P Aina De Torner Vidal (Barcelona, Spain) 揭示早发性胰腺癌：来自真实世界队列的临床、分子和治疗见解Unveiling Early-Onset Pancreatic Cancer: clinical, molecular and therapeutic insights from a real-world cohort 3181P Erwan Vo Quang (Paris, France) 免疫检查点抑制剂在MSI-H/dMMR晚期胰腺腺癌中的疗效：一项国际队列的更新分析Efficacy of immune checkpoint inhibitors in MSI-H/dMMR advanced pancreatic adenocarcinoma: updated analysis of an international cohort 3182P Kreina S. Vega Cano (Barcelona, Spain) 根据化疗顺序划分的晚期胰腺导管腺癌（PDAC）真实世界结局Real-world outcomes according to chemotherapy sequencing in advanced pancreatic ductal adenocarcinoma (PDAC) 3183P Morten Karsdal (Herlev, Denmark) 癌症相关成纤维细胞（CAFs）和肿瘤纤维化的液体活检用于评估接受纳武利尤单抗/放疗±伊匹木单抗或吉西他滨/白蛋白结合型紫杉醇±托珠单抗（tocilizumab）治疗的胰腺癌患者的疗效和生存Liquid biopsy of cancer-associated fibroblasts (CAFs) and tumor fibrosis for assessment of response and survival in pancreas cancer patients treated with Nivolumab/radiotherapy ± Ipilimumab or Gemcitabine/Nab-Paclitaxel ± Tocilizumab 3184P Daniel A. King (Lake Success, United States of America) 抗PAUF单克隆抗体PBP1510治疗转移性胰腺腺癌的安全性与疗效Safety and Efficacy of PBP1510, an Anti-PAUF Monoclonal Antibody, in Metastatic Pancreatic Adenocarcinoma 3185P Katherine G. Roth (Duarte, United States of America) PARP抑制剂和铂类化疗改善胰腺腺癌生存，且不依赖于HRD状态PARP inhibitors and Platinum Chemotherapy Improve Survival in Pancreatic Adenocarcinoma Independent of HRD Status 3186TiP Cindy Neuzillet (Boulogne-Billancourt, France) 优化一线NALIRIFOX方案并探索微生物群在胰腺癌二线治疗中的作用：PRODIGE 105 GERCOR PANORAMIX研究Optimizing 1st-line NALIRIFOX and Exploring the Role of Microbiota in 2nd-line Pancreatic Cancer Treatment: The PRODIGE 105 GERCOR PANORAMIX study 3187TiP Maria Pia Morelli (Houston, United States of America) 一项评估Navlimetostat（BMS-986504）联合化疗治疗可切除/交界可切除（队列1）、局部晚期不可切除（队列2）和转移性（队列3）MTAP缺失胰腺癌的II期研究A Phase II Study Evaluating Navlimetostat (BMS-986504) and chemotherapy in resectable/borderline resectable (cohort 1), locally advanced, unresectable (cohort 2), and metastatic (cohort 3) MTAP-deleted Pancreatic Cancer. 3188TiP Do-Youn Oh (Seoul, Republic of Korea) 靶向EphA2的Bicycle药物偶联物（BDC）Nuzefatide Pevedotin治疗转移性胰腺导管腺癌（PDAC）患者的2期研究Phase 2 Study of Nuzefatide Pevedotin, an EphA2-targeting Bicycle Drug Conjugate (BDC), in Patients (Pts) With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) 3189TiP Eileen M. O’Reilly (New York, United States of America) 进行中试验——MAPKeeper-301：Atebimetinib联合改良吉西他滨和白蛋白结合型紫杉醇方案对比标准吉西他滨和白蛋白结合型紫杉醇治疗转移性胰腺导管腺癌患者的3期随机、开放标签研究Trial In Progress- MAPKeeper-301: A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus Standard Gemcitabine and nab-Paclitaxel for Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma 3190TiP Teresa Macarulla Mercade (Barcelona, Spain) setidegrasib联合mFOLFIRINOX或NALIRIFOX一线治疗KRAS G12D突变转移性胰腺导管腺癌（PDAC）的3期双盲随机试验：进行中的试验A Phase 3, double-blind, randomized trial of setidegrasib + mFOLFIRINOX or NALIRIFOX as first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (PDAC) harboring KRAS G12D mutations: Trial in progress 3191eP Shuai Xiang (Beijing, China) 蛋白质组学驱动的机器学习策略实现新发糖尿病患者胰腺癌的早期检测Proteomic-driven machine learning strategy enables early detection of pancreatic cancer in new-onset diabetes 3192eP Miguel García-Bartolomé (Valencia, Spain) 术后TAV16 ctDNA检测分子残留病灶并预测胰腺癌切除术后复发Postoperative TAV16 ctDNA detects molecular residual disease and predicts relapse after pancreatic cancer resection 3193eP Santiago Sucre (Miami, United States of America) Avutometinib联合defactinib（AvDf）联合或不联合吉西他滨和白蛋白紫杉醇（GnP）治疗既往经治的KRAS突变胰腺导管腺癌（PDAC）患者Avutometinib plus defactinib (AvDf) with or without gemcitabine and nab-Paclitaxel (GnP) in previously treated patients with pancreatic ductal adenocarcinoma (PDAC) harboring KRAS mutations 3194eP Maroua Boujemaa (Tunis, Tunisia) 突尼斯胰腺癌的临床与胚系基因组特征：基因组稳定性及表观遗传通路参与的证据Clinical and Germline Genomic Characterization of Pancreatic Cancer in Tunisia: Evidence for Genome Stability and Epigenetic Pathway Involvement 3195eP Anke Onnekink (Leiden, Netherlands) 携带CDKN2A/p16胚系致病变异个体的胰腺导管腺癌基因组特征Genomic Characterization of Pancreatic Ductal Adenocarcinomas in Individuals with a Germline CDKN2A/p16 Pathogenic Variant 3196eP Carmen Cobos Lama (Madrid, Spain) 杂交捕获二代测序作为PDAC胚系基因组变异筛查工具的应用Hybrid-capture next-generation sequencing as a screening tool for germline genomic alterations in PDAC 3197eP Yung-yeh Su (Tainan City, Taiwan) 胰腺导管腺癌中KRAS突变特异性信号传导与转录程序KRAS Mutation-Specific Signalling and Transcriptomic Programmes in Pancreatic Ductal Adenocarcinoma 3198eP Fengwei Xu (Hang Zhou, China) 靶向PD-L1的ADCplex递送泛KRAS分子胶和伊立替康，在临床前胰腺癌模型中显示出强效抗肿瘤活性且毒性降低PD-L1–Targeted ADCplex Delivering a Pan-KRAS Molecular Glue and Irinotecan Demonstrates Potent Antitumor Activity With Reduced Toxicity in Preclinical Pancreatic Cancer Models 3199eP Shiwei Guo (Shanghai, China) PDAClassify：一种基于甲基化的分类器，用于胰腺导管腺癌的无创分子分型PDAClassify: a methylation-based classifier for non-invasive molecular subtyping of pancreatic ductal adenocarcinoma 3200eP Haripriya Andanamala (Oklahoma City, United States of America) SMAD4和HRD突变决定局限期胰腺癌新辅助化疗的不同应答SMAD4 and HRD Mutations Dictate Divergent Neoadjuvant Chemotherapy Responses in Localized Pancreatic Cancer 3201eP Ujjwal Soni (Oklahoma City, United States of America) 局限期胰腺癌中SMAD4和HRD共突变患者的治疗选择Treatment Selection in Patients with Concurrent SMAD4 and HRD Mutations in Localized Pancreatic Cancer 3202eP Ashish Sharma (New Haven, United States of America) PDAC治疗背景下肿瘤突变负荷解读：FDA阈值仅识别1.3%无预后信号的患者，而更高TMB与化疗患者的不良生存相关Treatment-context-specific tumor mutational burden interpretation in PDAC: the FDA threshold identifies 1.3% of patients without prognostic signal, while higher TMB associates with adverse survival in chemotherapy-treated patients 3203eP Jianfeng Huang (Guangzhou, China) 脾动脉灌注化疗对比全身化疗治疗晚期胰体/尾癌的疗效与安全性：一项真实世界研究Efficacy and Safety of Splenic Artery Infusion Chemotherapy Compared With Systemic Chemotherapy in Advanced Pancreatic Body/Tail Cancer: A Real-World Study 3204eP Aniek E. Van Diepen (Maastricht, Netherlands) 晚期胰腺癌疼痛患病率与强度：一项全国性前瞻性队列研究Pain prevalence and intensity in advanced pancreatic cancer: a nationwide prospective cohort study 3205eP Stefania Gkoura (Athens, Greece) 液体活检检测不可切除胰腺癌RAS突变：与生物标志物、临床参数及肿瘤分子特征的相关性——一项前瞻性观察研究RAS Mutation Detection by Liquid Biopsy in Unresectable Pancreatic Cancer: Correlation with Biomarkers, Clinical Parameters, and Tumor Molecular Features. A Prospective Observational Study 3206eP Deema Al Zoubi (Damascus, Syria) MDCT上肿瘤-血管接触的纵向量化评估作为胰头腺癌血管侵犯及可切除性的预测指标：一项前瞻性研究Longitudinal Tumor–Vessel Contact on MDCT as a Quantitative Predictor of Vascular Invasion and Resectability in Pancreatic Head Adenocarcinoma: A Prospective Study 3207eP David L. Bajor (Cleveland, United States of America) Ivosidenib联合mFOLFIRINOX治疗可切除胰腺导管腺癌（PDA）患者的I期单中心开放标签剂量递减和扩展研究A Phase I, Single-Center, Open-Label, Dose De-escalation and Expansion Study of Ivosidenib Plus mFOLFIRINOX in Patients With Resectable Pancreatic Ductal Adenocarcinoma (PDA) 3208eP Makoto Shinoto (Chiba, Japan) 碳离子放疗治疗不可切除胰腺癌的I期剂量递增研究A phase I dose-escalation study of carbon-ion radiotherapy for unresectable pancreatic cancer 3209eP Juan Du (Nanjing, China) LAPC中NALIRIFOX对比GnP诱导化疗联合PD-1抑制剂序贯SBRT的多中心随机对照II期试验Comparison of NALIRIFOX vs GnP Induction Chemotherapy Combined with PD-1 Inhibitor followed by sequential SBRT in LAPC: A Multi-Center, Randomized Controlled, Phase II Trial 3210eP Seok Jae Huh (Busan, Republic of Korea) 胰腺癌根治性胰切除术后自体自然杀伤细胞辅助治疗联合标准化疗的I期研究延长随访结果Extended follow-up results of a phase I study of adjuvant autologous natural killer cell therapy combined with standard chemotherapy after curative pancreatectomy for pancreatic cancer. 3211eP Kuirong Jiang (Nanjing, China) 脂质体伊立替康联合奥沙利铂及S-1或5-氟尿嘧啶/亚叶酸钙辅助治疗切除术后胰腺导管腺癌：一项多中心随机II期研究Liposomal irinotecan combined with oxaliplatin and S-1 or 5-fluorouracil/leucovorin as adjuvant therapy for resected pancreatic ductal adenocarcinoma: a multicenter randomized phase II study 3212eP Shiwei Guo (Shanghai, China) NALIRIFOX治疗高危可切除胰腺癌：多中心随机开放标签研究NALIRIFOX in high-risk resectable pancreatic cancer: multicenter，randomized, open-label study 3213eP Songul Kucukcelebi (Rotterdam, Netherlands) 立体定向放疗联合IMM-101疫苗治疗少转移性胰腺癌：MEPANC试验的安全性、可行性与免疫调节结果Stereotactic Radiotherapy and IMM-101 Vaccination in Oligometastatic Pancreatic Cancer: Safety, Feasibility, and Immunomodulatory Outcomes of the MEPANC Trial 3214eP Junjie Hang (Changzhou, China) 减剂量短疗程脂质体伊立替康联合卡培他滨二线治疗晚期胰腺癌的疗效与安全性：一项多中心II期研究The Efficacy and Safety of Reduced-dose and Short-course Regimen of Liposomal Irinotecan Plus Capecitabine as Second-Line Therapy for Advanced Pancreatic Cancer: A Multicenter Phase II Study 3215eP Jiujie Cui (Shanghai, China) ALTER-PA-001试验更新结果：安罗替尼联合Benmelstobart加AG方案对比AG方案一线治疗转移性胰腺癌的多中心开放标签随机II期研究Updated Results of the ALTER-PA-001 Trial: A Multicenter, Open-Label, Randomized Phase II Study of Anlotinib Plus Benmelstobart in Combination with AG Versus AG Alone as First-Line Treatment for Metastatic Pancreatic Cancer 3216eP Nono Brano (Chongqing, China) 奥拉帕利维持治疗BRCA突变胰腺导管腺癌的临床评估：来自III期试验、真实世界证据及SEER数据库的见解Clinical Evaluation of Olaparib Maintenance Therapy in BRCA-Mutated Pancreatic Ductal Adenocarcinoma: Insights from Phase III Trials, Real-World Evidence, and the SEER Database 3217eP Giancarlo Del Gaudio (Naples, Italy) 多学科团队管理对临界可切除及局部晚期胰腺癌临床结局的影响：MDT前时代与MDT时代治疗患者的单中心对比研究Impact of Multidisciplinary Team Management on Clinical Outcomes in Borderline Resectable and Locally Advanced Pancreatic Cancer: A Single Center Comparative Study of patient treated in the Pre-MDT and MDT Era 3218eP Daniel Herrero Rivera (Madrid, Spain) 诊断与治疗延误对局限期及转移性胰腺癌的临床影响：一项西班牙多中心回顾性队列研究Clinical impact of diagnostic and treatment delays in localized and metastatic pancreatic cancer: a Spanish multicenter retrospective cohort study 3219eP Joecelyn Kirani Tan (Manchester, United Kingdom) 合并代谢共病胰腺癌死亡率的年龄分层趋势：1999至2020年美国劳动年龄人群的不成比例上升Age-Stratified Trends in Pancreatic Cancer Mortality with Co-occurring Metabolic Comorbidities: A Disproportionate Rise in Working-Age Adults in the United States, 1999 to 2020 3220eP Joecelyn Kirani Tan (Manchester, United Kingdom) 1999至2020年美国合并代谢共病的胰腺癌死亡率的种族与民族模式Racial and Ethnic Patterns in Pancreatic Cancer Mortality with Metabolic Comorbidity Co-occurrence in the United States, 1999 to 2020 3221eP Joecelyn Kirani Tan (Manchester, United Kingdom) 1999至2020年美国合并代谢共病的胰腺癌死亡率的地区及城乡模式Regional and Rural-Urban Patterns in Pancreatic Cancer Mortality with Metabolic Comorbidity Co-occurrence in the United States, 1999 to 2020 3222eP Marta M. Fudalej (Warsaw, Poland) 治疗前全身炎症指数预测胰腺癌患者死亡率的临床应用价值Clinical Utility of Pre-treatment Systemic Inflammation Indices in Predicting Mortality in Pancreatic Cancer Patients 3223eP Chien-Jui Huang (Tainan City, Taiwan) 超越D-二聚体：纤溶酶原激活物抑制剂-1（PAI-1）增强胰腺癌血栓预测及预后分层Beyond D-dimer: Plasminogen activator inhibitor-1 (PAI-1) Enhances Thrombosis Prediction and Prognostic Stratification in Pancreatic Cancer 3224eP Souhaila Akir (Rabat, Morocco) 胰腺癌胆道引流：转移性疾病是否影响ERCP成功率？Biliary Drainage in Pancreatic Cancer: Does Metastatic Disease Influence ERCP Success? 3225eP Sandra Martínez Badal (Barcelona, Spain) 胰腺癌中KRAS相关意义未明变异的功能与定量表征Functional and quantitative characterization of KRAS-associated variants of uncertain significance in pancreatic cancer 3226eP Elena Artamonova (Moscow, Russian Federation) empegfilgrastim一级预防改善转移性胰腺癌（mPC）患者FOLFIRINOX治疗后的相对剂量强度：一项系统综述与匹配调整间接比较（MAIC）结果Primary prophylaxis (PP) with empegfilgrastim improves relative dose intensity after FOLFIRINOX in metastatic pancreatic cancer (mPC) patients: results of a systematic review and matching-adjusted indirect comparison (MAIC) 3227eP Yunok Oh (Seoul, Republic of Korea) 单细胞图谱分析与AI筛选揭示STRA6为克服PDAC间质介导耐药的精准治疗靶点Single-Cell Profiling and AI-Based Screening Reveal STRA6 as a Precision Therapeutic Target to Overcome Stromal-Mediated Resistance in PDAC 3228eP Elizabeth A. Fung (Vancouver, Canada) 胰腺导管腺癌（PDAC）患者代谢共病与胚系致病变异（PGVs）的分析Analysis of metabolic comorbidities in patients with pancreatic ductal adenocarcinoma (PDAC) and pathogenic germline variants (PGVs) 3229eP Sara Durdiakova (Bratislava, Slovakia) CLDN18.2在胰腺导管腺癌中的表达及临床意义：一项荟萃分析CLDN18.2 Expression and Clinical Significance in Pancreatic Ductal Adenocarcinoma: A Meta-Analysis 3230eP Taehun Kim (Seoul, Republic of Korea) 晚期胰腺癌FOLFIRINOX诱导治疗后的化疗假期：无化疗间期（CFI）时长的可行性及预测因素Chemotherapy Holiday After Induction FOLFIRINOX in Advanced Pancreatic Cancer: Feasibility and Predictors of Chemotherapy-Free Interval (CFI) Length 3231eP Ditila Doracaj (Tirana, Albania) 阿尔巴尼亚胰腺导管腺癌代谢功能障碍的临床病理学关联Clinicopathological associations of metabolic dysfunction in pancreatic ductal adenocarcinoma in Albania 3232eP Yang Liu (Tianjin, China) 晚期胰腺导管腺癌不可逆电穿孔治疗后CA19-9的早期控制Early CA19-9 control after irreversible electroporation in advanced pancreatic ductal adenocarcinoma 3233eP Peter Hosein (Miami, United States of America) ELI-002 7P mKRAS T细胞调节后转移性胰腺癌的根治Eradication of metastatic pancreatic cancer after ELI-002 7P mKRAS T cell modulation 3234eP Bruno Buecher (Paris, France, CEDEX 5) 胰腺导管腺癌多基因Panel检测的法国推荐意见French recommendations on multigene panel testing in pancreatic ductal adenocarcinoma 3235eP Xiaofeng Xue (Suzhou, China) 胰管内支架不能降低临床相关术后胰瘘但增加胰切除术后急性胰腺炎：一项倾向评分匹配分析Internal pancreatic duct stents do not reduce clinically relevant postoperative pancreatic fistula but increase post-pancreatectomy acute pancreatitis: A propensity score-matched analysis 3236eP Xu Pan (Beijing, China) 胰腺导管腺癌的大规模单细胞空间解析Large-Scale Single-Cell Spatial Dissection of Pancreatic Ductal Adenocarcinoma 3237eP Kreina S. Vega Cano (Barcelona, Spain) 晚期胰腺癌（APC）中基于5-氟尿嘧啶（5FU）和吉西他滨（GEM）化疗获益差异的表型特征Phenotypes of differential benefit from 5-fluorouracil (5FU) and gemcitabine (GEM) based chemotherapy in Advanced Pancreatic Cancer (APC) 3238eP Hsin Hui Wang (Taipei City, Taiwan) 靶向TXNDC5重塑促结缔组织增生及代谢微环境并使PDAC对PD-1阻断敏感Targeting TXNDC5 reshapes the desmoplastic and metabolic landscape and sensitizes PDAC to PD-1 blockade 3239eP Daniele Santini (Latina, Italy) 转移性胰腺导管腺癌（mPDAC）的治疗（Tx）策略：来自跨国基于实践与证据的筛查和共识（SCOPE）焦点小组的结果Treatment (Tx) strategies to manage metastatic pancreatic ductal adenocarcinoma (mPDAC): Results from the multinational Screening and COnsensus based on Practices and Evidence (SCOPE) focus groups 3240eP Anika Forstreuter (Hamburg, Germany) 超越BMI：骨骼肌与内脏脂肪作为胰腺癌的独立预后标志物Beyond BMI: skeletal muscle and visceral fat as independent prognostic markers in pancreatic cancer 3241eP Sacha El Khoury (Houston, United States of America) PDAC中CLDN18.2的表达：不依赖KRAS状态及IV期的预后价值CLDN18.2 Expression in PDAC: KRAS Independence and Stage IV Prognostic Value 3242eP Daryna Bulakh (Kaunas, Lithuania) OXTR rs53576基因多态性在胰腺癌中的预后价值Prognostic Value of the OXTR rs53576 gene polymorphism in Pancreatic Cancer 3243eP Hyo Shik Shin (Seoul, Republic of Korea) 肿瘤相关巨噬细胞来源的CXCL16在胰腺导管腺癌中的作用Role of tumor-associated macrophage-derived CXCL16 in pancreatic ductal adenocarcinoma 3244eP Hila Fishman (Haifa, Israel) 肿瘤电场治疗（TTFields）联合FOLFIRINOX或KRAS抑制剂治疗胰腺癌的临床前评估Preclinical evaluation of Tumor Treating Fields (TTFields) with FOLFIRINOX or KRAS inhibition in pancreatic cancer 3245eP Marine Valery (Villejuif, France) 胰腺和肝脏肿瘤加速诊断路径的影响：Gustave Roussy癌症中心多学科胃肠肿瘤团队的经验Impact of an Accelerated Diagnostic Pathway for Pancreatic and Hepatic Tumors: Experience from a Multidisciplinary Gastro-intestinal Oncology team at Gustave Roussy Cancer Center. 3246eP Akhil Deepak Vatvani (Tangerang, Indonesia) 直接口服抗凝药对比低分子肝素用于接受FOLFIRINOX治疗的胰腺腺癌患者：一项倾向评分匹配的真实世界分析Direct Oral Anticoagulants Versus Low-Molecular-Weight Heparin in Pancreatic Adenocarcinoma Patients Receiving FOLFIRINOX: A Propensity-Matched Real-World Analysis 3247eP Carol Cremin (Vancouver, Canada) 携带ATM胚系致病变异的胰腺导管腺癌的临床特征与结局：一项回顾性分析Clinical characteristics and outcomes of pancreatic ductal adenocarcinoma with germline pathogenic ATM variants: a retrospective analysis 3248eP Leonardo E. Da Cunha (Sao Jose do Rio Preto, Brazil) FOLFIRINOX对比吉西他滨联合白蛋白紫杉醇一线治疗转移性胰腺癌：真实世界证据的系统综述与荟萃分析First-line FOLFIRINOX versus Gemcitabine plus Nab-Paclitaxel for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis of Real-World Evidence 3249eP Daniela Iacono (Rome, Italy) 瘤内磷-32微粒（OncoSil®）治疗不可切除局部晚期胰腺腺癌患者的真实世界经验Intratumoral phosphorus-32 microparticles (OncoSil®) in unresectable locally advanced pancreatic adenocarcinoma patients: a real-world experience 3250eP Antoine Jourdain (Paris, France) 胰腺癌确诊时的营养不良、肌少症、高代谢及微量营养素缺乏：NUTRIPAN队列Malnutrition, sarcopenia, hypermetabolism and micronutrient deficiencies at pancreatic cancer diagnosis: the NUTRIPAN cohort 3251eP Ana Paula O. Victorino (Rio de Janeiro, Brazil) 适合序贯治疗的晚期胰腺癌患者的总生存：巴西真实世界数据Overall survival in advanced pancreatic cancer patients eligible for sequential treatment: real-world data from in Brazil 3253eP Navindi De Silva (Vancouver, Canada) 标准与改良吉西他滨/白蛋白紫杉醇给药方案在转移性胰腺癌中的真实世界生存结局Real-World Survival Outcomes Associated with Standard Versus Modified Gemcitabine/Nab-Paclitaxel Dosing Schedules in Metastatic Pancreatic Cancer 3254eP Ana Paula O. Victorino (Rio de Janeiro, Brazil) 晚期胰腺癌的治疗机会丧失：巴西真实世界队列中的早期死亡模式、基线危险因素及快速进展者特征Treatment opportunity loss in advanced pancreatic cancer: early mortality patterns, baseline risk factors, and characterization of rapid progressors in a brazilian real-world cohort 3255eP Jesus Rodriguez Pascual (Madrid, Spain) 晚期胰腺癌的治疗顺序安排：一项大规模真实世界分析Treatment sequencing in advanced pancreatic cancer: a large real-world analysis 3256eP Joecelyn Kirani Tan (Manchester, United Kingdom) 美国合并代谢共病的胰腺癌死亡率二十年全国趋势：一项基于人群的横断面分析（1999–2020）Two-Decade National Trends in Pancreatic Cancer Mortality with Metabolic Comorbidities in the United States: A Population-Based Cross-Sectional Analysis (1999–2020) 3257eP Diyora Kurambaeva (Tashkent, Uzbekistan) 胰腺癌手术根治性的个体化把握：标准切除与解剖靶向切除的荟萃分析与系统综述Tailoring Surgical Radicality in Pancreatic Cancer: A Meta-Analysis and Systematic Review of Standard versus Anatomically Targeted Resections 3258eP Sergio Perez-Fernandez (Barcelona, Spain) 胰腺导管腺癌根治性切除术后复发的多维分析Multidimensional analysis of recurrence after curative-intent resection of pancreatic ductal adenocarcinoma. 3259eP Maryam Taherioun Isfahani (Tehran, Iran) 临界可切除或局部晚期胰腺导管腺癌新辅助治疗后的手术时机：系统综述与荟萃分析Surgical Timing After Neoadjuvant Therapy in Borderline Resectable or Locally Advanced Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis 3260eP Patricia Capdevila Gaudens (Valencia, Spain) 从临界可切除到可切除：胰腺腺癌新辅助治疗后谁真正接受了手术From borderline to resectable: who truly reaches surgery after neoadjuvant therapy for pancreatic adenocarcinoma 3261eP Blanca María Fernández Bellón (Madrid, Spain) 光子计数探测器CT用于胰腺肿瘤：诊断准确性、图像质量及辐射剂量的系统综述与荟萃分析Photon-counting detector CT for pancreatic neoplasms: a systematic review and meta-analysis of diagnostic accuracy, image quality, and radiation dose 3262eP Yasmin B. Da Cruz (Curitiba, Brazil) 非转移性胰腺导管腺癌根治性手术的利用不足：来自SEER分析的社会经济与种族决定因素Underutilization of Curative-Intent Surgery in Non-Metastatic Pancreatic Ductal Adenocarcinoma: Socioeconomic and Racial Determinants from a SEER Analysis 3263eP Xiaofei Zhang (Shanghai, China) 戈沙妥珠单抗治疗多线经治晚期胰腺癌的预后因素与安全性Prognostic factors and safety of sacituzumab govitecan in heavily pretreated advanced pancreatic cancer 3264eP Xuyao Zhang (Shanghai, China) 靶向PD-1和IL-18R的三特异性抗体在胰腺癌中以更优安全性增强抗肿瘤免疫Trispecific Antibody Targeting PD-1 and IL-18R Enhances Antitumor Immunity with Superior Safety Profile in Pancreatic Cancer 3265eP Burak Alper Zengin (Istanbul, Türkiye) 早发转移性胰腺癌的临床特征与生存结局Clinical Characteristics and Survival Outcomes in Early-Onset Metastatic Pancreatic Cancer 3266eP Ravi Kumar Paluri (Winston-Salem, United States of America) 循环microRNA纵向动态变化作为胰腺癌诱导化疗联合SBRT治疗后应答及生存的探索性预测指标Longitudinal circulating microRNA dynamics as exploratory predictors of response and survival in pancreatic cancer treated with induction chemotherapy followed by SBRT 3267eP Alihan Altunay (Antalya, Türkiye) 临界可切除胰腺癌的新辅助化疗：临床结局及其与CT肿瘤密度的关联Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer: Clinical Outcomes and association with CT Tumor Density 3268eP Sehyun Park (Szeged, Hungary) 微创对比开放胰切除术治疗可切除胰腺导管腺癌的肿瘤学结局：系统综述与荟萃分析Oncologic Outcomes of Minimally Invasive Versus Open Pancreatectomy for Resectable Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis 3269eP Mutiu Jimoh (Lagos, Nigeria) 私立医疗机构中的胰腺癌：尼日利亚拉各斯的治疗与生存结局——十年回顾Pancreatic Cancer in Private Care: Treatment _ Survival Outcomes from Lagos, Nigeria – A 10-Year Review 3270eP Jiayue Zou (Suzhou, China) 术前活化部分凝血活酶时间作为初始切除胰腺导管腺癌早期复发及生存的独立预测因子Preoperative activated partial thromboplastin time as an independent predictor of early recurrence and survival in upfront resected pancreatic ductal adenocarcinoma 3272eTiP Haiqi Lu (Hangzhou, China) 优替德隆注射液治疗标准治疗难治的晚期胰腺癌的单臂探索性临床试验A single-arm exploratory clinical trial of Utidelone injection for advanced pancreatic cancer refractory to standard therapy 3273eTiP Einar Sulheim (Oslo, Norway) PS101声学簇疗法联合化疗治疗局部晚期胰腺癌（ENACT试验）PS101 in Acoustic Cluster Therapy with Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer (ENACT trial) ∞ EPILOGUE写在最后胰腺癌是本届 ESMO 变化最剧烈的瘤种：三年前 KRAS 还只是转化研究的题目，如今已经有 III 期、有围手术期设计、有疫苗平台。但也要保持清醒——胰腺癌的临床决策仍然高度依赖体能状态与营养支持，新药能否真正改变生存曲线，还要看随后的 III 期读出。「KRAS 之后，胰腺癌需要的是能进入一线、进入围手术期的完整证据链，而不只是漂亮的早期缓解率。」 END 本文数据整理自 ESMO Congress 2026 官方公开日程（含 LBA 及专场报道），中文题目为 AI 辅助翻译，仅供检索参考，请以英文原文为准。如果你觉得今天这篇有收获，欢迎点赞、在看、转发三连，See You！扫码关注我，上学堂呦版权声明：本平台旨在帮助医疗卫生专业人士更好地了解相关疾病领域最新进展。本平台对发布的资讯内容，并不代表同意其描述和观点，仅为提供更多信息。如该等信息被用于了解资讯以外的目的，本平台及作者不承担相关责任。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。仅供医疗卫生专业人士为了解资讯使用，该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。

2026-09-29

·患友招募

复发难治的结直肠癌患者别慌！5款创新药临床试验深度指南和希望

结直肠癌治疗减负指南复发难治的结直肠癌患者别慌！5款创新药临床试验深度指南和希望同样是晚期结直肠癌，有人靠温和创新药活了5年仍能正常生活，有人硬扛高强度化疗半年就无法耐受，核心差异在于是否选对适配自身体质与经济状况的治疗方案。本文专门整理了适配弱体质人群的创新药临床试验信息，帮大家少花冤枉钱、少遭不必要的罪。一、晚期结直肠癌患者的真实痛点国内每年新发结直肠癌超56万例，近40%患者确诊时已属晚期，失去手术长期控制/延缓进展机会。大部分晚期患者都面临两难困境：要么硬扛化疗，恶心呕吐、骨髓抑制、手脚麻木等副作用轮番发作，体质弱的老人、术后恢复/好转期患者根本无法耐受，反而越治身体越差；要么用高价靶向药，进口药月费动辄数万，即便进入医保也有严格适应症限制，后线治疗、特殊分型患者无法报销，普通家庭撑数月就会掏空积蓄。另有近30%患者为罕见突变分型，常规治疗疗效极差，几乎陷入无药可用的绝境。 ⚠️ 注意事项提示：第一，别不分分型乱吃药：EGFR单抗仅对RAS野生型患者有效，KRAS突变患者服用完全无效，白花费用还耽误治疗；第二，别盲目追求高强度治疗：体质差的患者强行使用三药联合化疗，只会摧毁自身免疫力，生存期反而更短；第三，别信放弃正规治疗：所谓「癌症治疗方」「野菜疗法」无任何临床验证，不少患者服用后出现肝肾损伤，反而错过优选/理想治疗时机；第四，别把临床试验当「小白鼠试验」：正规临床试验均经过严格伦理审批，使用的是已过前期验证的创新药，比来源不明的仿制药安全性更高，还能节省数十万治疗费用。二、结直肠癌常规治疗方案与局限目前结直肠癌标准治疗按分型分层选择：早期优先手术切除，中晚期采用化疗联合靶向/免疫治疗。MSI-H/dMMR亚型患者可使用免疫治疗，RAS野生型用抗EGFR单抗，RAS突变用抗血管生成药，HER2阳性、KRAS G12C突变的特殊分型患者可选药物极少。常规治疗局限十分明显：化疗副作用大，近40%体质弱患者无法耐受足剂量化疗；靶向药大多需长期服用，即便医保相关后每月仍需数千到上万元，长期经济压力极大；且几乎所有靶向药用药半年到一年都会出现耐药，后线患者常陷入无药可用的困境。客观来看：> 目前全球药企针对结直肠癌的创新药研发，均向「更温和、更精准、更划算」方向发展：皮下注射的免疫药无需输液，副作用比传统PD-1低一半；口服精准靶向药无需住院，在家即可服用，对正常细胞损伤小，体质弱患者也可耐受。正规临床试验是普通患者接触这些前沿新药的优选/理想途径，药物与相关检查均按方案执行，可大幅减轻家庭经济负担，完全适合体质弱、经济压力大、常规治疗耐药的患者考虑。五项在研临床试验新药深度解读与机会 📋评价恩沃利单抗注射液治疗dMMR/MSI-H晚期结直肠癌及其他晚期实体瘤的安全性和有效性的II期临床研究项目简介试验登记号：CTR20181127 药物类别：PD-L1单域抗体生物创新药试验期数：II期申办方：思路迪医药为国内专注肿瘤精准医疗和创新药研发的领先企业，多个创新药已进入注册临床阶段，研发实力获业内认可。招募人群：dMMR/MSI-H亚型的晚期结直肠癌患者，及其他dMMR/MSI-H亚型的晚期实体瘤患者，既往接受过标准治疗后进展，或无法耐受常规化疗的患者也可纳入。试验药物介绍药物作用机制与原理：可精准识别躲避免疫系统监控的MSI-H/dMMR肿瘤细胞，同时解除免疫细胞的抑制信号，让免疫细胞直接杀伤肿瘤细胞。作为单域抗体，其分子量仅为普通抗体的1/10，可更快渗透到肿瘤组织内部，起效尽快快于普通PD-1，对正常细胞影响更小。治疗数据和同类药物对比：已公布的II期临床数据显示，针对晚期结直肠癌患者的客观缓解率（ORR）超过40%，远高于常规化疗的15%左右；且副作用发生率比普通静脉注射的PD-1/PD-L1低30%左右，3级以上严重免疫相关不良反应的发生率不到5%，体质弱的患者耐受性更好。设计方案试验设计：多中心、单臂、开放标签的关键注册II期研究分组方式：所有入组患者均接受恩沃利单抗单药治疗，无对照组给药方式：皮下注射，每周1次，无需住院输液，操作简单家属即可帮忙注射给药剂量：按研究方案设定的固定剂量给药给药周期：每28天为一个治疗周期，直到疾病进展或出现不可耐受的毒性，全程定期开展安全性和疗效监测筛选入排要求与患者权益：上述项目内容展现有限，详细的筛选要求和入排标准以及受试者相关权益请点击链接详细咨询了解。对比点评这款是国内首个皮下注射的PD-L1抑制剂，给药方便无需频繁跑医院输液，副作用更轻，特别适合体质弱、不耐受输液和常规PD-1副作用的MSI-H/dMMR晚期结直肠癌患者，可省下十几万的免疫药费用，符合分型的患者可优先了解。 📋评价重组抗EGFR人鼠嵌合单克隆抗体联合伊立替康治疗转移性结直肠癌的安全性和有效性的II/III期临床研究项目简介试验登记号：CTR20130630 药物类别：抗EGFR人鼠嵌合单克隆抗体靶向药试验期数：II/III期申办方：百泰生物是国内最早开展单抗药物研发的高新技术企业，研发的尼妥珠单抗是国内首个上市的人源化单抗药物，生产工艺成熟稳定。招募人群：RAS/BRAF野生型的转移性结直肠癌患者，既往未接受过EGFR单抗治疗，可耐受伊立替康化疗，或者既往接受一线化疗后进展的患者。试验药物介绍药物作用机制与原理：传统进口EGFR单抗如西妥昔单抗，人鼠嵌合度稍低，过敏、皮疹等不良反应发生率更高，这款药通过优化的人鼠嵌合技术，可精准结合肿瘤细胞表面的EGFR靶点，阻断肿瘤细胞的生长信号通路，同时诱导免疫细胞杀伤肿瘤细胞，对正常细胞影响更小，不良反应发生率更低。治疗数据和同类药物对比：II期临床数据显示，联合伊立替康治疗转移性结直肠癌的客观缓解率达到45%左右，和进口西妥昔单抗的疗效相当，而皮疹、输液过敏等不良反应的发生率比进口药低25%左右，体质弱的患者耐受性更好。设计方案试验设计：多中心、随机、开放标签、阳性药对照的II/III期注册研究分组方式：按1:1随机分为试验组（试验药+伊立替康）和对照组（西妥昔单抗+伊立替康）给药方式：静脉滴注，每2周1次给药剂量：按体表面积计算给药剂量给药周期：每28天为一个治疗周期，直到疾病进展或出现不可耐受的毒性筛选入排要求与患者权益：上述项目内容展现有限，详细的筛选要求和入排标准以及受试者相关权益请点击链接详细咨询了解。对比点评这款药疗效和进口西妥昔单抗相当，副作用更轻，对于RAS野生型、需要用EGFR单抗的转移性结直肠癌患者来说，是性价比更高的选择，尤其是对进口药过敏或者不耐受的患者，非常适合考虑，可省下十几万的靶向药费用。 📋评价盐酸安罗替尼胶囊治疗标准治疗后进展的转移性结直肠癌的安全性和有效性的IIB期临床研究项目简介试验登记号：CTR20140777 药物类别：多靶点口服抗血管生成靶向药试验期数：IIB期申办方：正大天晴药业是国内知名的创新型制药企业，研发的安罗替尼是国内首个获批的多靶点抗血管生成口服靶向药，覆盖多个实体瘤适应症，研发和生产实力处于国内领先水平。招募人群：既往接受过至少2线标准治疗后进展的转移性结直肠癌患者，无严重基础疾病，能够耐受口服给药。试验药物介绍药物作用机制与原理：一方面同时抑制VEGFR、PDGFR、FGFR三个和肿瘤血管生成相关的靶点，切断肿瘤的营养供应，阻止肿瘤生长；另一方面抑制肿瘤细胞的增殖信号，直接阻止肿瘤细胞分裂，双管齐下发挥作用，且为口服制剂，无需输液住院，对身体负担更小。治疗数据和同类药物对比：IIB期临床数据显示，针对标准治疗失败的转移性结直肠癌患者，中位无进展生存期（PFS）达到5.6个月，比同类抗血管生成药瑞戈非尼的3.1个月长近80%，而且手足综合征、高血压等不良反应的发生率比瑞戈非尼低20%左右，患者耐受性更好。设计方案试验设计：多中心、随机、双盲、安慰剂对照的IIB期研究分组方式：按2:1随机分为试验组（安罗替尼）和对照组（安慰剂）给药方式：口服，每日1次，连续服用2周停药1周给药剂量：按研究方案设定的固定剂量给药给药周期：每21天为一个治疗周期，直到疾病进展或出现不可耐受的毒性筛选入排要求与患者权益：上述项目内容展现有限，详细的筛选要求和入排标准以及受试者相关权益请点击链接详细咨询了解。对比点评这款药是口服的多靶点抗血管药，给药方便无需住院，副作用小，特别适合后线治疗无药可用、体质弱不能耐受化疗的转移性结直肠癌患者，在家即可服药，可大幅提升生活质量，还能省下十几万的治疗费用，后线患者可以重点考虑。 📋评价图卡替尼片治疗HER2阳性晚期实体瘤（含结直肠癌）的安全性、耐受性和药代动力学的I期临床研究项目简介试验登记号：CTR20220676 药物类别：口服HER2小分子酪氨酸激酶抑制剂（TKI）靶向药试验期数：I期申办方：西雅图遗传学公司（Seagen）是全球领先的ADC和小分子靶向药研发企业，研发的多款ADC和TKI药物已在全球获批上市，覆盖乳腺癌、胃癌等多个瘤种，研发实力获全球医学界认可。招募人群：HER2阳性的晚期实体瘤患者，包括既往接受过标准治疗后进展的HER2阳性晚期结直肠癌患者，无严重心功能异常，能够耐受口服给药。试验药物介绍药物作用机制与原理：用药后药物可精准穿过血脑屏障，专门结合肿瘤细胞上的HER2靶点，阻断HER2的下游信号通路，阻止肿瘤细胞生长和转移，且不会影响正常细胞的功能，因此副作用比化疗轻很多，还能有效控制脑转移病灶，无需接受全脑放疗。治疗数据和同类药物对比：国外已经公布的III期临床数据显示，图卡替尼联合曲妥珠单抗治疗HER2阳性晚期结直肠癌的客观缓解率达到46%，中位总生存期（OS）达到24.1个月，比传统的HER2抑制剂疗效提升近一倍，而且腹泻、肝损伤等不良反应的发生率比同类HER2 TKI低30%左右，耐受性更好。设计方案试验设计：多中心、开放标签、剂量爬坡和剂量扩展的I期研究分组方式：所有入组患者均接受图卡替尼单药治疗，无对照组给药方式：口服，每日2次给药剂量：按预设的剂量爬坡梯度给药，逐步确定优选/理想给药剂量给药周期：每21天为一个治疗周期，直到疾病进展或出现不可耐受的毒性筛选入排要求与患者权益：上述项目内容展现有限，详细的筛选要求和入排标准以及受试者相关权益请点击链接详细咨询了解。对比点评这款药是全球首个针对HER2阳性结直肠癌有明确疗效的小分子TKI，还能透过血脑屏障控制脑转移，副作用小，特别适合HER2阳性、常规治疗耐药、尤其是合并脑转移的晚期结直肠癌患者，此前这类患者几乎没有理想治疗方案，这个项目是非常难得的机会。 📋评价GEC255片治疗KRAS G12C突变的晚期实体瘤（含结直肠癌）的安全性、耐受性和药代动力学的I期临床研究项目简介试验登记号：CTR20212486 药物类别：口服KRAS G12C小分子抑制剂靶向药试验期数：I期申办方：加科思药业是国内专注于KRAS等难成药靶点研发的领先创新药企，拥有自主研发的变构抑制剂技术平台，多个KRAS抑制剂已进入全球多中心临床阶段，研发实力获国际资本和医学界认可。招募人群：携带KRAS G12C突变的晚期实体瘤患者，包括既往接受过标准治疗后进展的晚期结直肠癌患者，无严重基础疾病，能够耐受口服给药。试验药物介绍药物作用机制与原理：KRAS G12C突变的肿瘤细胞此前无针对性药物可精准打击，这款药是专门针对KRAS G12C突变的变构抑制剂，可精准结合突变的KRAS蛋白，将其锁定在失活状态，阻断生长信号传递，从而杀死肿瘤细胞，对正常的KRAS蛋白没有影响，因此副作用非常小，体质弱的患者也可耐受。治疗数据和同类药物对比：前期临床数据显示，针对KRAS G12C突变的晚期结直肠癌患者，客观缓解率达到30%左右，中位无进展生存期达到5.3个月，而此前这类患者常规化疗的客观缓解率不到10%，中位PFS不到2个月，疗效提升非常明显，而且3级以上严重不良反应的发生率不到10%。设计方案试验设计：多中心、开放标签、剂量爬坡和剂量扩展的I期研究分组方式：所有入组患者均接受GEC255单药治疗，无对照组给药方式：口服，每日1次或2次给药剂量：按预设的剂量爬坡梯度给药，逐步确定优选/理想给药剂量给药周期：每21天为一个治疗周期，直到疾病进展或出现不可耐受的毒性筛选入排要求与患者权益：上述项目内容展现有限，详细的筛选要求和入排标准以及受试者相关权益请点击链接详细咨询了解。对比点评这款药是针对KRAS G12C突变的精准靶向药，此前这类患者几乎没有可用的靶向药，常规治疗疗效很差，这款药不仅疗效好，副作用还轻，特别适合携带KRAS G12C突变、常规治疗耐药的晚期结直肠癌患者，是难得的新治疗机会。想了解更多治疗、临床研究相关内容，可以点击以下链接阅读往期文章：确诊结直肠癌后，这份临床试验指南帮你找到适合自己的方案，写给患者和家属的6个新药入门手册【结直肠癌】确诊结直肠癌，钱花了、罪受了、治疗却没起色？这里有选择，26年第四批临床试验药治疗，用上前沿临床试验药！【结直肠癌】化疗患者陷入 “做了遭罪、不做怕复发” 的两难？2026第三批前沿药/进口药/仿制药即将给你带来选择；康心医疗｜【结直肠癌】2026年1月：结直肠癌有多凶险？患者家属收藏的防、治、避坑指南+6款临床试验药解读康心医疗｜【直肠癌】12月临床试验新药治疗汇总：结直肠癌治疗困局！5项临床研究，为生命续航！总结与建议 📋5款药物选择建议不同病情的患者可按自身情况匹配：①若为MSI-H/dMMR亚型的晚期结直肠癌患者，体质弱不耐受输液和化疗，优先选择恩沃利单抗项目；②若为RAS/BRAF野生型的转移性结直肠癌患者，需要使用EGFR单抗，对进口药不耐受或想减轻经济负担，选择重组抗EGFR单抗项目；③若为标准治疗后进展的晚期结直肠癌患者，无特殊突变，后线无药可用，优先选择安罗替尼项目；④若为HER2阳性的晚期结直肠癌患者，尤其是合并脑转移，选择图卡替尼项目；⑤若为携带KRAS G12C突变的晚期结直肠癌患者，选择GEC255项目。结直肠癌的治疗已经进入精准分型时代，无需盲目跟风他人的治疗方案，也不要因为是晚期就轻易放弃。正规的临床试验不是「当小白鼠」，所有项目都经过严格的伦理审批，优先保障受试者的安全，不仅能用上前沿的温和创新药，还能大幅减轻家庭经济负担，对于体质弱、经济压力大的患者来说，是非常值得考虑的选择。目前该领域有多项临床试验正在全国多中心开展，如果大家想咨询报名或不确定自己是否符合上述临床试验的入组条件，再或者想要了解更多该疾病的临床试验项目，可以私信联系我们或者点击下面图片小程序咨询了解详情，我们将会免费为您提供一对一的病情评估和入组指导等服务。一起少走弯路。【文章摘要】本文针对结直肠癌尤其是体质弱、经济压力大的患者，梳理治疗注意事项要点、常规治疗局限，深度解读5款创新药临床试验，给出清晰的选择建议，帮患者找到适配的治疗方案。【互动话题】你或者身边的结直肠癌患者目前遇到的较大/显著治疗困境是什么？欢迎在评论区留言交流。【标签】#结直肠癌治疗 #临床试验 #创新靶向药 #免疫治疗 #患者就医指南 ⚠️免责声明：本文仅为医学科普，不属于医疗广告。临床试验为医学科学研究，不保证受试者获得临床获益，存在未知风险。能否参加研究，必须由研究中心结合病历综合评估，提交信息不等于可以入组。文中提及补贴均为受试者交通、采血营养补偿。

2026-09-27

·大道论药

RAS靶向治疗：从不可成药到广谱时代

2026年8月，美国食品药品监督管理局（FDA）正式批准Revolution Medicines的daraxonrasib（Rasonque™）上市，用于治疗既往接受过至少一次系统治疗或不适合接受多药系统治疗的转移性胰腺导管腺癌成人患者。此次批准比PDUFA目标日期提前了约6.5个月。这一批准，标志着RAS这一长期被视为“不可成药”的靶点，终于迎来了首款获批的广谱靶向药物。 Daraxonrasib的获批，不仅为“癌症之王”胰腺癌患者带来了历史性的生存突破，更深刻地揭示了RAS靶向药物的未来发展方向，从“选择性狙击”走向“广谱覆盖”。 01 追本溯源 RAS基因的发现，是人类肿瘤生物学史上的里程碑事件。 1982年，三个独立的研究小组几乎同时发现，人类膀胱癌细胞中存在一种与Harvey鼠肉瘤病毒ras基因同源的人类基因，其第12位密码子发生了点突变——甘氨酸被缬氨酸取代（G12V）。这是人类首次在实体瘤中确认了致癌基因的突变。此后，科学家相继发现了HRAS、KRAS和NRAS三个RAS基因家族成员。 RAS蛋白是一种小GTP酶，在细胞内部充当着“分子开关”的核心角色。当RAS与GTP结合时处于“开启”（ON）状态，激活下游的RAF-MEK-ERK、PI3K-AKT等多条促增殖、促生存信号通路；当GTP被水解为GDP后，RAS回到“关闭”（OFF）状态。 RAS基因发生突变后，其GTP水解能力受损，导致RAS蛋白持续处于“开启”状态，不断向细胞核发送“生长”信号，驱动细胞癌变和无限增殖。 RAS是人类肿瘤中最常见的突变致癌基因，约30%的人类肿瘤携带RAS突变。在胰腺导管腺癌（PDAC）中，致癌性RAS突变占92%，其中绝大多数为KRAS（91.8%），最常见的KRAS突变类型包括G12D（39.9%）、G12V（28.6%）和G12R（14.6%）。在结直肠癌中约40%-50%，在非小细胞肺癌中约30%。然而，RAS蛋白表面光滑、缺乏明显的药物结合口袋，加之其与GTP的皮摩尔级亲和力，使得直接靶向RAS的小分子药物研发举步维艰。此后的四十年里，RAS被科学界公认为“不可成药”靶点。 02 破局之道 RAS“不可成药”的魔咒，直到2013年才出现裂痕。 2013年，Kevan Shokat团队在《自然》杂志上报道了首个可靶向KRAS G12C突变体的共价小分子，开创性地利用了G12C突变引入的半胱氨酸残基，设计出能与该半胱氨酸共价结合的化合物。这一策略打开了KRAS G12C抑制剂的大门。此后，安进的sotorasib（Lumakras™）于2021年获得FDA加速批准，成为全球首款上市的KRAS G12C抑制剂，用于治疗携带KRAS G12C突变的非小细胞肺癌。紧随其后，Mirati Therapeutics（BMS收购）的adagrasib（Krazati™）于2022年获批。KRAS G12C抑制剂的成功，首次证明了RAS靶点是可以成药的。但KRAS G12C抑制剂存在明显的局限性：G12C仅占KRAS突变的一小部分（在NSCLC中约10%-15%，在胰腺癌中仅占约1-2%）。而且这类抑制剂只靶向处于GDP结合“关闭”状态的RAS，对持续“开启”的活化态RAS无能为力。胰腺癌患者中超过90%携带RAS突变——这意味着占胰腺癌绝大多数的患者无法从KRAS G12C抑制剂中获益。此前，以KRAS G12C抑制剂为代表的多款靶向药，在胰腺癌这个适应症上普遍折戟。真正的突破来自于机制层面的创新。 Revolution Medicines另辟蹊径，开发出了一种 “分子胶”：药物分子先与细胞内的亲环蛋白A（Cyclophilin A）非共价结合，形成的复合物再与处于GTP结合“开启”状态的RAS蛋白结合，形成三元复合物，立体阻断RAS与下游效应蛋白的结合。这一机制使药物Daraxonrasib（Rasonque）能够广谱抑制多种RAS突变类型（G12、G13、Q61等）以及野生型RAS。这也是该类药物的核心作用机制，不是“关掉”开关，而是直接“按住”那个持续“开启”的开关。 03 上市竞品接下来，我们挑选出已上市的典型药物，做一个横向对比，看看它们在胰腺癌治疗领域临床数据的真实强度。（表1：已上市药物PDAC临床数据对比）从上述临床证据来看，胰腺癌治疗领域呈现出鲜明的“疗效断层”。 1.Daraxonrasib是唯一在胰腺癌III期RCT中取得OS和PFS双主要终点阳性结果的药物。其中位OS达13.2个月，死亡风险降低60%（HR=0.40），ORR达30%，三项核心指标均以压倒性优势超越标准化疗。更关键的是，其获益不依赖于RAS突变分型，覆盖约92%的胰腺癌患者，这是其他任何已上市药物未能实现的广谱覆盖能力。 2.Sotorasib虽为全球首款KRAS G12C抑制剂，但在胰腺癌中证据薄弱。其数据仅来自I/II期单臂研究（n=38），ORR 21%、中位OS 6.9个月，至今未获胰腺癌适应症批准，仅被NCCN指南纳入后线推荐。核心原因在于G12C突变在胰腺癌中仅占1-2%，适用人群极窄，且其靶向GDP结合“关闭”状态的机制在胰腺癌中打击效率有限。 3.免疫检查点抑制剂在未经选择的PDAC中疗效极为有限。 Nivolumab+Ipilimumab在BRCA突变后线患者中ORR仅14%；PD-1/PD-L1抑制剂汇总分析显示OS平均仅延长0.92个月，PFS和ORR均无显著获益。胰腺癌的“冷肿瘤”微环境是免疫单药疗效受限的根本原因。 4.Zolbetuximab的失败尤为值得关注。尽管在胃癌中取得成功，但在CLDN18.2阳性胰腺癌的II期GLEAM研究中，中位OS 13.7 vs 13.6个月（HR=1.00），完全未能改善生存。这一结果提示，同一靶点在胃癌与胰腺癌中的生物学价值可能存在本质差异，胰腺癌的靶向治疗不能简单复制其他瘤种的成功经验。 5.Nimotuzumab和Cadonilimab分别代表了中国在胰腺癌靶向和免疫联合治疗领域的探索。 Nimotuzumab已在中国获批用于晚期胰腺癌，II期数据显示ORR 25%、DCR 100%，但样本量极小（n=10），需更大规模验证。 Cadonilimab的回顾性研究提示双特异性抗体联合化疗可能改善PFS，但回顾性设计限制了证据级别。在已上市药物中，Daraxonrasib是当前胰腺癌治疗领域疗效证据最为坚实、生存获益最为显著的药物。 Sotorasib受限于突变亚型覆盖率低和证据级别不足，免疫检查点抑制剂受限于胰腺癌“冷肿瘤”特性. Zolbetuximab则因靶点生物学差异未能复制胃癌成功。 04 Revolution Medicines管线 Daraxonrasib的成功，仅仅是Revolution Medicines围绕RAS(ON)靶点布局的开始。该公司构建了深度管线的RAS(ON)抑制剂家族，针对不同突变类型开发选择性抑制剂： Zoldonrasib（RMC-9805）是一款RAS(ON) G12D选择性口服共价抑制剂。 2026年1月，该药获得FDA突破性疗法认定，用于治疗KRAS G12D突变的非小细胞肺癌。在NSCLC的临床I期试验结果（RMC-9805-001）中，接受zoldonrasib 1200 mg每日一次治疗的患者（n=18），客观反应率（ORR）达61%，疾病控制率（DCR）为89%，中位首次缓解时间为1.4个月。在胰腺癌领域，zoldonrasib联合方案数据更为亮眼：（表2：zoldonrasib联合方案主要数据对比）二线zoldonrasib + daraxonrasib联合治疗的中位PFS达9.6个月，6个月PFS率为71%。 Elironrasib（RMC-6291）是一款RAS(ON) G12C选择性抑制剂，目前处于I期临床阶段。在既往接受过KRAS G12C OFF状态抑制剂治疗的NSCLC患者中，elironrasib单药治疗ORR达50%，展示了克服第一代G12C抑制剂耐药的潜力。 RMC-5127是一款RAS(ON) G12V选择性抑制剂，已于2026年1月完成首例患者给药，目前处于I期临床阶段。 05 展望未来 Daraxonrasib的获批，标志着RAS靶向治疗从“0到1”的历史性跨越，但RAS靶向药物的征途才刚刚开始。正如Daraxonrasib的临床数据所揭示的——二线归属已定，一线、联合、跨瘤种三块最大的价值区间格局未定。 1.联合治疗是明确的趋势。 Daraxonrasib单药一线治疗胰腺癌的探索性数据显示ORR达47%，而联合化疗的ORR达58%。 2026年8月，百济神州已宣布计划开展daraxonrasib与其PRMT5抑制剂、EGFRxMETxMET三抗的联合治疗研究。 2.拓展适应症是另一重要方向。 Daraxonrasib的III期临床试验覆盖了非小细胞肺癌、结直肠癌等多个瘤种。Revolution的另一款Zoldonrasib在NSCLC中已获突破性疗法认定。 3.新型机制的探索同样令人期待。除了小分子抑制剂，RAS靶向降解剂（如百济神州的BG-85738）、RAS切割蛋白生物制剂、肿瘤定向递送系统等新型治疗模式正在兴起。结语从1982年RAS基因的发现，到2026年首款泛RAS抑制剂的获批，人类用了44年时间，将“不可成药”的靶点变成了“可治疗”的疾病。这不仅是药物研发的胜利，更是基础科学向临床转化的一次完美诠释。而随着全球数十款RAS靶向药物的持续推进，我们有理由相信，RAS突变驱动的癌症患者，正迎来一个充满希望的新时代。（关注公众号，后台回复“RAS”，获取相关资料。） *声明：资料源于官方、公开信息，侵删；未经允许，不得转载；个人观点，非诊疗建议；如有谬误，欢迎指正。往期文章： FDA：全球首创RAS抑制剂，改写“癌王”治疗格局 BMS：全球第二款KRAS G12C抑制剂，破解“不可成药”靶点安进：全球首个KRAS G12C抑制剂，破解“不可成药”靶点难题学习交流：关注公众号，后台回复“进群”。

100 项与尼妥珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	尼妥珠单抗	L01XC	DB06192

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
胰腺癌	中国	百泰生物药业有限公司	2023-06-07
头颈部鳞状细胞癌	印尼	Innogene Kalbiotech Pte Ltd.	2022-10-19
鼻咽癌	中国	Biotech Pharmaceuticals Pty Ltd	2008-01-07
胶质瘤	乌克兰	Oncoscience AG	2007-10-10
头颈部肿瘤	印度	Biocon Biopharmaceuticals Pvt Ltd.	2006-09-11

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胃食管交界处腺癌	临床3期	中国	百泰生物药业有限公司	2024-08-01
胃食管交界处癌	临床3期	中国	百泰生物药业有限公司	2024-08-01
胃腺癌	临床3期	中国	百泰生物药业有限公司	2024-08-01
转移性结直肠癌	临床3期	-	百泰生物药业有限公司	2024-04-03
晚期头颈部鳞状细胞癌	临床3期	中国	百泰生物药业有限公司	2021-11-01
弥漫内生性脑桥神经胶质瘤	临床3期	中国	百泰生物药业有限公司	2021-04-03
宫颈鳞状细胞癌	临床3期	中国	百泰生物药业有限公司	2016-05-10
食管鳞状细胞癌	临床3期	中国	百泰生物药业有限公司	2015-11-13
转移性食管鳞状细胞癌	临床3期	中国	百泰生物药业有限公司	2015-11-01
宫颈癌	临床3期	阿尔及利亚	-	2015-10-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EANO2026	N/A	-	12	Radiotherapy + Nimotuzumab/Vinorelbine regimen (NV)	願醖鹹淵繭鹽鹽構鑰範(鬱鏇衊鏇構觸醖網築醖) = 壓鏇夢築衊願鹹簾鹽構淵淵艱鬱簾構窪壓積壓 (淵廠鏇鬱夢餘選願憲鏇, 0 ~ 43) 更多	不佳	2026-09-24
NCT03766178 (Pubmed \| J Immunother Cancer)	临床2期	晚期食管鳞状细胞癌二线 EGFR amplification \| MUC16 mutations \| NOTCH3 mutations ... 更多	46	Camrelizumab 200 mg + nimotuzumab 400 mg	積夢齋膚鬱構窪齋廠夢(窪衊獵鹽糧醖廠壓繭蓋) = 積鏇顧遞鏇鹹壓遞憲願範願積構網壓齋範艱餘 (遞簾襯鬱廠範製齋製襯, 19.5 ~ 48.0) 更多	积极	2026-09-01
				Camrelizumab 200 mg + nimotuzumab 400 mg	積夢齋膚鬱構窪齋廠夢(窪衊獵鹽糧醖廠壓繭蓋) = 艱積夢餘鬱窪繭製繭蓋範願積構網壓齋範艱餘 (遞簾襯鬱廠範製齋製襯 )
NCT07353723 (Pubmed \| Front Immunol)	临床2期	扁桃体肿瘤新辅助	20	Nimotuzumab + Toripalimab + Nab-paclitaxel + Carboplatin	鹹艱範獵衊遞築鹽鹽糧(壓蓋鬱壓觸願蓋壓築艱) = 壓鬱構鹹壓範鬱簾範壓選襯淵糧鏇衊獵鑰簾獵 (餘願壓製糧醖壓積繭膚 ) 更多	积极	2026-07-14
NCT05717790 (ASCO_Breakthrough2026)	临床3期	晚期鼻咽癌	172	Nimotuzumab plus standard therapy (Stage III-IVa nasopharyngeal carcinoma)	壓衊鬱網選願壓艱壓鑰(憲衊淵醖範衊願製鑰鏇) = 簾鑰鏇築製醖夢餘衊鹽鏇鑰膚獵膚襯範鬱鹹襯 (鹹選廠糧鏇艱觸積齋積 ) 更多	积极	2026-06-25
				Standard therapy (Stage III-IVa nasopharyngeal carcinoma)	壓衊鬱網選願壓艱壓鑰(憲衊淵醖範衊願製鑰鏇) = 網獵鹹遞衊網鏇窪網壓鏇鑰膚獵膚襯範鬱鹹襯 (鹹選廠糧鏇艱觸積齋積 ) 更多
ASCO_Breakthrough2026	N/A	头颈部肿瘤	108	Concurrent chemoradiotherapy (inj. cisplatin 30 mg/m2 weekly)	鏇鬱鬱醖積淵積遞顧製(壓簾簾範淵膚衊繭鏇願) = Toxicity was grade 2 and 3 in both group some patient only grade 4 toxicity in both arm 願襯壓衊廠艱鹹壓網網 (獵蓋觸遞製艱醖壓窪糧 )	积极	2026-06-25
				Concurrent chemoradiotherapy (inj. cisplatin 30 mg/m2 weekly) + Inj nimotuzumab 200mg/weekly
NCT04475016 (ASCO_Breakthrough2026)	临床2期	阴茎鳞状细胞癌新辅助	29	Toripalimab plus nimotuzumab combined with taxol-based chemotherapy (TNT regimen)	顧蓋選憲廠鑰鏇鹽廠廠(夢鏇構網夢遞鏇鏇鹹餘) = 窪窪願壓淵淵鑰鏇夢鏇願築網鬱鬱顧簾艱範壓 (築鏇衊顧餘衊淵壓範壓, 54.1 ~ 88.2) 更多	积极	2026-06-25
				Toripalimab plus nimotuzumab combined with taxol-based chemotherapy (TNT regimen) (non-pCR group)	衊鹹願積襯齋膚積廠繭(鏇積構網簾鹹壓範範築) = 醖網鏇膚憲築簾鑰網鑰膚築夢醖鏇顧淵簾憲醖 (餘夢憲鏇鑰衊顧簾繭觸, 12 ~ NR) 更多
NCT06879691 (ASCO2026)	临床3期	头颈部肿瘤	194	nimotuzumab + analgesics + CCRT	構鬱繭齋壓構構網鹹艱(獵鹽鏇構鏇憲憲衊鬱構) = 繭壓觸壓廠廠簾壓選構獵膚網顧夢憲醖鑰壓積 (艱糧遞齋積範餘壓衊膚 ) 更多	积极	2026-05-29
				analgesics + CCRT	構鬱繭齋壓構構網鹹艱(獵鹽鏇構鏇憲憲衊鬱構) = 窪願鹹網鹽衊鬱網簾鏇獵膚網顧夢憲醖鑰壓積 (艱糧遞齋積範餘壓衊膚 ) 更多
ASCO2026	N/A	局部晚期头颈部鳞状细胞癌	75	Concurrent chemoradiotherapy (CCRT) (Intermediate high-risk (e.g., pT3-4, N2-3))	鏇餘鹹網壓糧簾網鏇積(鏇構夢襯衊鑰壓艱窪襯) = 憲醖衊構餘觸製築膚製選鬱觸蓋艱製蓋觸願築 (鬱製憲構艱憲餘積窪窪 ) 更多	积极	2026-05-29
				nimotuzumab plus CCRT (Extranodal extension/positive margins)	鏇餘鹹網壓糧簾網鏇積(鏇構夢襯衊鑰壓艱窪襯) = 淵鏇積製壓淵糧淵繭積選鬱觸蓋艱製蓋觸願築 (鬱製憲構艱憲餘積窪窪 ) 更多
ASCO2026	N/A	胰腺癌新辅助 EGFR expression	100	AG regimen alone	願獵齋積獵鹹製襯遞積(積鹽壓繭觸遞積餘憲築) = 鏇網糧選鹽壓鹹衊鑰網廠憲壓醖鹹餘觸壓積簾 (鹹遞製壓繭襯壓衊膚鹽 ) 更多	积极	2026-05-29
				AG regimen + nimotuzumab	願獵齋積獵鹹製襯遞積(積鹽壓繭觸遞積餘憲築) = 廠艱遞製範蓋鹽鏇積簾廠憲壓醖鹹餘觸壓積簾 (鹹遞製壓繭襯壓衊膚鹽 ) 更多
NCT06048913 (ASCO2026)	临床2期	食管鳞状细胞癌	56	Nimotuzumab plus S-1 and concurrent radiotherapy	構艱願鬱獵夢鹽壓鏇襯(夢構廠鬱範築餘廠艱齋) = 蓋淵鏇繭製繭網獵範獵製製顧遞願鬱鑰遞齋遞 (糧範醖夢餘壓願壓衊衊, 55.5 ~ 80.1) 更多	积极	2026-05-29